Saltar al contenido
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Lenguaje
Todos los Campos
Título
Autor
Materia
Número de Clasificación
ISBN/ISSN
Etiqueta
Buscar
Avanzado
Future of flu vaccines. Expedi...
Citar
Describir
Enviar este por Correo electrónico
Imprimir
Exportar Registro
Exportar a RefWorks
Exportar a EndNoteWeb
Exportar a EndNote
Enlace Permanente
Future of flu vaccines. Expediting clinical trials in a pandemic.
Mostrar otras versiones (1)
Detalles Bibliográficos
Autores principales:
Pollard, A
,
Reiner, A
,
John, T
,
Sheasby, E
,
Snape, M
,
Faust, S
,
Collinson, A
,
Finn, A
,
Heath, P
,
Miller, E
Formato:
Journal article
Lenguaje:
English
Publicado:
2009
Existencias
Descripción
Otras Versiones (1)
Ejemplares similares
Vista Equipo
Ejemplares similares
Future of flu vaccines. Expediting clinical trials in a pandemic.
por: Pollard, A, et al.
Publicado: (2009)
Relationships between reactogenicity and age, dose number and immunogenicity in 937 children receiving two doses of ASO3(B)-adjuvanted split virion or whole virus H1N1 influenza A 2009 pandemic vaccines
por: Walker, W, et al.
Publicado: (2011)
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
por: Waddington, C, et al.
Publicado: (2010)
Safety and immunogenicity of AS03 B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study
por: Waddington, C, et al.
Publicado: (2010)
Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
por: Waddington, C, et al.
Publicado: (2010)